Journal: Journal of Clinical Microbiology

Article Title: Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins

doi: 10.1128/JCM.01344-19

Figure Lengend Snippet: Modal MICs and susceptibility categorization (CLSI/EUCAST) of study isolates and antibiotics a

Article Snippet: Both isolates were susceptible to the agents in this study, with the exception of the K. pneumoniae isolate against cefazolin (MIC 4 μg/ml, intermediate [ 15 ]). table ft1 table-wrap mode="anchored" t5 TABLE 1 caption a7 Isolate Antibiotic MIC (μg/ml) (categorical interpretation via CLSI/EUCAST breakpoints) b , c Meropenem Imipenem Levofloxacin Cefazolin Cefepime Piperacillin-tazobactam E. coli ATCC 25922 ≤0.063 (S/S) 0.25 (S/S) ≤0.063 (S/S) 2 (S/–) ≤0.063 (S/S) 4/4 (S/S) K. pneumoniae ATCC 13883 0.25 (S/S) NT NT 4 (I/–) 0.125 (S/S) 4/4 (S/S) Open in a separate window a S, susceptible; I, intermediate; NT, not tested; –, unavailable. b CLSI susceptibility breakpoints for E. coli and K. pneumoniae are ≤1 μg/ml (meropenem and imipenem), ≤0.5 μg/ml (levofloxacin), ≤2 μg/ml (cefazolin), ≤2 μg/ml (cefepime), and ≤16/4 μg/ml (piperacillin-tazobactam) ( 15 ). c EUCAST susceptibility breakpoints for E. coli and K. pneumoniae are ≤2 μg/ml (meropenem and imipenem), ≤0.5 μg/ml (levofloxacin), ≤1 μg/ml (cefepime), and ≤8/4 μg/ml (piperacillin-tazobactam).

Techniques: